#### Sweet Child of Mine Use of Dextrose Gel for Neonatal hypoglycemia

#### Petruska Maak, M.D













Neonatal hypoglycemia is common: 5-15% of neonates



- Neonatal hypoglycemia is common: 5-15% of neonates
- Leading cause of admission to the NICU



- Neonatal hypoglycemia is common: 5-15% of neonates
- Leading cause of admission to the NICU
- Occur in at-risk groups (IDM, preterms, SGA, LGA).



- Neonatal hypoglycemia is common: 5-15% of neonates
- Leading cause of admission to the NICU
- Occur in at-risk groups (IDM, preterms, SGA, LGA).
- Untreated → Brain Injury & higher risk for poor developmental outcome.



- Neonatal hypoglycemia is common: 5-15% of neonates
- Leading cause of admission to the NICU
- Occur in at-risk groups (IDM, preterms, SGA, LGA).
- Untreated → Brain Injury & higher risk for poor developmental outcome.
- Frequently managed with ACTIVE treatments: formula, IV dextrose, separation from mother.



- Neonatal hypoglycemia is common: 5-15% of neonates
- Leading cause of admission to the NICU
- Occur in at-risk groups (IDM, preterms, SGA, LGA).
- Untreated → Brain Injury & higher risk for poor developmental outcome.
- Frequently managed with ACTIVE treatments: formula, IV dextrose, separation from mother.
- Prevalence is increasing : pre-terms & maternal factors





Controversial definition, thresholds & management



- Controversial definition, thresholds & management
- Harris: 47 mg/dL (2.6 mmol/L)



- Controversial definition, thresholds & management
- Harris: 47 mg/dL (2.6 mmol/L)
- **2011 AAP--**> keep > 45 mg/dL



- Controversial definition, thresholds & management
- Harris: 47 mg/dL (2.6 mmol/L)
- **2011** AAP--> keep > 45 mg/dL
- 2015 Endo Society:



- Controversial definition, thresholds & management
- Harris: 47 mg/dL (2.6 mmol/L)
- **2011** AAP--> keep > 45 mg/dL
- 2015 Endo Society:
  - >48 h of life = risk for neuro injury.



- Controversial definition, thresholds & management
- Harris: 47 mg/dL (2.6 mmol/L)
- **2011** AAP--> keep > 45 mg/dL
- 2015 Endo Society:
  - >48 h of life = risk for neuro injury.
  - Target > 50 mg/dL




#### Current Guidelines AAP Committee on fetus and Newborn 2011

Screening and Management of Postnatal Glucose Homeostasis in Late Preterm and Term SGA, IDM/LGA Infants

[(LPT) Infants 34 – 36677 weeks and SGA (screen 0-24 hrs); IDM and LGA ≥34 weeks (screen 0-12 hrs)]

#### ASYMPTOMATIC



#### Target glucose screen ≥45 mg/dL prior to routine feeds

\* Glucose dose = 200 mg/kg (dextrose 10% at 2 mL/kg) and/or IV infusion at 5–8 mg/kg per min (80–100 mL/kg per d). Achieve plasma glucose level of 40-50 mg/dL.

Symptoms of hypoglycemia include: Irritability, tremors, jitteriness, exaggerated Moro reflex, high-pitched cry, seizures, lethargy, floppiness, cyanosis, apnea, poor feeding.

YEAR	AUTHOR	METHODS	FINDINGS
2006	What is the neurodevelopmental outcome after neonatal HG in the first week of life?	<ul> <li>- 5225 references (1966 to 2005).</li> <li>- 46 potentially relevant articles</li> <li>- 18 studies included: 1583 infants.</li> </ul>	- 2 with high methodological quality
1988	Lucas	<ul> <li>661 preterm infants. 5 centers</li> <li>Infant formula vs preterm formula or supplements added to maternal milk .</li> <li>92% assessed at 18 months.</li> <li>Retrospective study;</li> </ul>	<ul> <li>Deficits if &gt; 3 days HG &lt; 45 mg/dL on &gt; 5 days.</li> <li>Low mental/motor skills, &gt; delays &amp; CP.</li> <li>Screening for ICH not uniformly done,</li> <li>Causal relationship vs adjustment</li> </ul>
2005	Brand	5 healthy term LGA, HG in 60 (80%); -Assessed at 4 years. Retrospective study, Tool (DDS) no Bayley	HG 60 (80%); NO significant differences between neonates with and without hypoglycemia
1988	Koh	<ul> <li>- 5 newborns evaluated by (BAER),</li> <li>7 infants/children evaluated by BAER;</li> <li>5 children evaluated by somatosensory evoked potentials (electric current stimulation).</li> </ul>	<ul> <li>BG &lt; 47 -&gt;Evoked potentials abnormal in 10 of 11.</li> <li>Abnormal sensory EP w/ BG 13 to 45</li> <li>Suggested different susceptibility to HG</li> </ul>
2012	Kjerstens	<ul> <li>832 preemies: 32-35-6/7 wks</li> <li>HG: 1 BG &lt; 30 within 72 hours of birth</li> <li>67 (8%) had HG. 42 w/BG 20-30</li> <li>25 w/glucose &lt; 20</li> <li>90% of these infants were NOT admitted to NICU</li> </ul>	<ul> <li>Assessed ~43-49 mos</li> <li>Parents report/ charts</li> <li>12 of 67w/BG &lt; 30 w/abnormal ASQ</li> <li>HG was associated with higher risk of DD in preterms 32- 35-6/7 wks</li> </ul>
2015	Kaiser	<ul> <li>-1943 born at Arkansas center 23-42 wks</li> <li>1395 newborn-student pairs (72%)</li> <li>440 (31.5%) preterm</li> <li>- Universal BG screen policy</li> <li>Eval infants with BG &lt; 45, &lt; 40, &lt; 35</li> <li>11 children w/ cognitive disability</li> <li>Retrospective population-based</li> </ul>	Early transient NB hypoglycemia was associated with decreased probability of proficiency on literacy and math test scores at age 10 years
2015	McKinlay	- Studies: Lucas (1988), Kjerstens (2012), Kaiser (2015)	All 3 studies raised concerns of poorer neurodevelopmental outcomes when preterm infants were hypoglycemic
2012	Tin	<ul> <li>BG drawn with labs at same time each day for 10 days</li> <li>566 preterm NICU infants</li> <li>47(8%) w/ BG &lt;45 on &gt; 3D</li> <li>11 had BG &lt; 36 on 3 days</li> <li>38 (6.7%) f/u up at age 15</li> </ul>	<ul> <li>Study population</li> <li>studies were designed to eval care unrelated to HG</li> <li>"Found no evidence to support the belief that recurrent low BG (&lt;45 mg/dl) in the first 10 days of life pose a hazard to preterm infants"</li> </ul>
2005	Burns "Symptomatic hypoglycemia may be associated with neurodevelopmental impairment – What do MRI scans show?	<ul> <li>- 84 infants with &gt; 1 episode early NH</li> <li>- 35 term, 37 to 42 weeks</li> <li>- Excluded: HIE, cong infection, brain anomalies dysmorphic features, genetics</li> <li>- 10 excluded because MRI at &gt; 6 weeks</li> <li>- 22 (63%) had transient NH that resolved with glucose administration and without recurrence</li> <li>- 27 (61%) symptomatic w/seizures</li> </ul>	<ul> <li>- 30 (86%) had severe HG&lt; 27 on &gt;1x</li> <li>- 5 had mild HG &gt; 27 to &lt; 47</li> <li>- More prevalent IUGR &amp; c-section</li> <li>- MRI ~ 9 days (1-42 d)</li> <li>- 33 (94%) : white matter abnormalities</li> <li>- No differences MRI transient vs prolonged/recurrent</li> <li>- Neurodevelopmental outcomes ~ 18 mos: 8 -normal,</li> <li>15 w/mild impairment, 8 w/moderate impairment, 3 w/</li> </ul>





Inexpensive, noninvasive, and easy to administer.



- Inexpensive, noninvasive, and easy to administer.
- Can be applied directly to the buccal mucosa for rapid correction



- Inexpensive, noninvasive, and easy to administer.
- Can be applied directly to the buccal mucosa for rapid correction
- Dosing is weight based (0.5ml/kg)



- Inexpensive, noninvasive, and easy to administer.
- Can be applied directly to the buccal mucosa for rapid correction
- Dosing is weight based (0.5ml/kg)
- Provides 400 mg/kg glucose (40% glucose + water and glycerin)



- Inexpensive, noninvasive, and easy to administer.
- Can be applied directly to the buccal mucosa for rapid correction
- Dosing is weight based (0.5ml/kg)
- Provides 400 mg/kg glucose (40% glucose + water and glycerin)
- Dose can be easily divided




- Inexpensive, noninvasive, and easy to administer.
- Can be applied directly to the buccal mucosa for rapid correction
- Dosing is weight based (0.5ml/kg)
- Provides 400 mg/kg glucose (40% glucose + water and glycerin)
- Dose can be easily divided
- Sublingual absorption rate is equal to IV dextrose




- Inexpensive, noninvasive, and easy to administer.
- Can be applied directly to the buccal mucosa for rapid correction
- Dosing is weight based (0.5ml/kg)
- Provides 400 mg/kg glucose (40% glucose + water and glycerin)
- Dose can be easily divided
- Sublingual absorption rate is equal to IV dextrose
- Promotes continued breast feeding and maternal bonding.







Harris et al, Lancet 2013




- Harris et al, Lancet 2013
- Randomized, DBPC trial




- Harris et al, Lancet 2013
- Randomized, DBPC trial
- Level 3 NICU. New Zealand 2008-2010.




- Harris et al, Lancet 2013
- Randomized, DBPC trial
- Level 3 NICU. New Zealand 2008-2010.
- 35-42 weeks PCA,



- Harris et al, Lancet 2013
- Randomized, DBPC trial
- Level 3 NICU. New Zealand 2008-2010.
- 35-42 weeks PCA,
- < 48 hrs old.</p>



- Harris et al, Lancet 2013
- Randomized, DBPC trial
- Level 3 NICU. New Zealand 2008-2010.
- 35-42 weeks PCA,
- < 48 hrs old.</p>
- At risk infants: SGA, LGA, IDM



#### The Sugar Babies Study

514 enrolled: 242 randomized

- 514 enrolled: 242 randomized
- 2 Groups: 40% Dextrose gel 200 mg/kg or placebo gel


- 514 enrolled: 242 randomized
- 2 Groups: 40% Dextrose gel 200 mg/kg or placebo gel
- Treatment threshold : BG < 47 mg/dl, Severe HG < 36 mg/dl</p>

- 514 enrolled: 242 randomized
- 2 Groups: 40% Dextrose gel 200 mg/kg or placebo gel
- Treatment threshold : BG < 47 mg/dl, Severe HG < 36 mg/dl</p>
- BG at 1hr, then qac x 24 then q6. 6 doses max in 48 hrs.

- 514 enrolled: 242 randomized
- 2 Groups: 40% Dextrose gel 200 mg/kg or placebo gel
- Treatment threshold : BG < 47 mg/dl, Severe HG < 36 mg/dl</p>
- BG at 1hr, then qac x 24 then q6. 6 doses max in 48 hrs.
- SQ continuos Glucose monitoring x 48-7days.

- 514 enrolled: 242 randomized
- 2 Groups: 40% Dextrose gel 200 mg/kg or placebo gel
- Treatment threshold : BG < 47 mg/dl, Severe HG < 36 mg/dl</p>
- BG at 1hr, then qac x 24 then q6. 6 doses max in 48 hrs.
- SQ continuos Glucose monitoring x 48-7 days.
- Primary Outcomes: Treatment failure with BG < 47mg/dl x 2</p>

- 514 enrolled: 242 randomized
- 2 Groups: 40% Dextrose gel 200 mg/kg or placebo gel
- Treatment threshold : BG < 47 mg/dl, Severe HG < 36 mg/dl</p>
- BG at 1hr, then qac x 24 then q6. 6 doses max in 48 hrs.
- SQ continuos Glucose monitoring x 48-7days.
- Primary Outcomes: Treatment failure with BG < 47mg/dl x 2</p>
- No adverse events



	Dextrose gel (n=118)	Placebo gel (n=119)	Relative risk or median difference (95% CI)	p value
Volume of study gel (mL/kg)	0-84 (0-43-2-44)	0-97 (0-47-2-49)	0-005 (-0-01 to 0-02)	0-45
Treatment failure	16 (14%)	29 (24%)	0.57 (0.33 to 0.98)	0-04
Dextrose administered as:				
Study gel				
Babies	118 (100%)	119 (100%)		
Dose (g/kg)	0-3 (0-2-1-0)	0	-	
Open-label gel*				
Babies	6 (5%)	13 (11%)	0-47 (0-18 to 1-18)	0.15
Dose (g/kg)	0-2 (0-1-0-4)	0-4 (0-2-0-6)	0-14 (0-00 to 0-20)	0-10
Intravenous bolus				
Babies	7 (6%)	13 (11%)	0-54 (0-23 to 1-31)	0.24
Dose (g/kg)	0-2 (0-2-0-2)	0-2 (0-1-1-0)	0-0001 (-0-004 to 0-20)	0.96
Intravenous infusion				
Babies	8 (7%)	17 (14%)	0-47 (0-21 to 1-06)	0-09
Dose (g/kg)	6-7 (2-0-10-6)	7-7 (3-7-14-6)	2-12 (-0-42 to 5-58)	0.10
Total Intravenous dextrose (g/kg)	7-1 (2-5-10-8)	8-3 (4-2-16-2)	2-55 (0-50 to 5-84)	0-09
Total dextrose from sources other than study gelt				
Babies	12 (10%)	28 (24%)	0-43 (0-23 to 0-81)	0-01
Dose (g/kg)	4-5 (0-2-10-8)	6-6 (0-2-16-2)	0-20 (-2-1 to 5-5)	0-51
Total dextrose from all sources				
Babies	118 (100%)	119 (100%)		
Dose (g/kg)	0-3 (0-2-11-4)	0-0 (0-0-16-2)	0.20 (0.19 to 0.23)	<0.0001
Feeding				
Breastfed babies	112 (95%)	113 (95%)	1-00 (0-94 to 1-06)	0-99
Feeds per baby	13 (1-29)	11 (1-24)	-1-00 (-3-00 to 0-00)	0.16
Babies receiving expressed breastmilk	100 (85%)	97 (82%)	1-04 (0-93 to 1-17)	0-60
Feeds per baby	4 (1-15)	6 (1-16)	1-00 (0-00 to 2-00)	0.02
Volume (mL/kg)	2-4 (0-1-96-1)	4-7 (0-0-43-6)	1-07 (0-14 to 2-37)	0-03
Babies receiving Infant formula	68 (58%)	72 (60%)	0-95 (0-77 to 1-18)	0-69
Feeds per baby	7 (1-21)	10 (1-24)	2.00 (0.00 to 4.00)	0-04
Volume (mL/kg)	41 (1-162)	58 (2-208)	11-06 (-3-01 to 26-89)	0.14
Admitted to NICU				
Babies (n)	45 (38%)	55 (46%)	0-83 (0-61 to 1-11)	0-24
For hypoglycaemia (n)	16 (14%)	30 (25%)	0-54 (0-31 to 0-93)	0-03

Data are n (%) or median (range), unless otherwise indicated. NICU-neonatal intensive-care unit. \*40% dextrose given according to usual clinical guidelines after the baby had failed treatment. †includes open-label and intravenous dextrose.

Table 2: Primary and secondary outcomes

		Dextrose gel (n=118)	Placebo gel (n=119)	Relative risk or m (95% CI)	edian difference	p value	
Volume of stud	y gel (mL/kg)	0-84 (0-43-2-44)	0.97 (0.47-2.49)		-02)	0-45	•
Treatment failu		16 (14%)	29 (24%)	0-57 (0-33 to 0-9	8)	0.04	
Dextrose admin	istered as:						
Study gel							
Babies		118 (100%)	119 (100%)				
Dose (g/kg)		0-3 (0-2-1-0)	0	-			
Open-label ge	el*						
Babies Dece (o (bo)		6 (5%)	13 (11%)	0-47 (0-18 to 1-1	-	0.15	
Dose (g/kg) Intravenous b		0-2 (0-1-0-4)	0-4 (0-2-0-6)	0-14 (0-00 to 0-2	0)	0-10	
Babies	nered .	7 (6%)	13 (11%)	0-54 (0-23 to 1-3	n	0.24	
Dose (g/kg)	)	0.2 (0.2-0.2)	0-2 (0-1-1-0)	0-0001 (-0-004 t	-	0.96	
Intravenous in					<i>.</i>		
Babies		8 (7%)	17 (14%)	0-47 (0-21 to 1-0	5)	0-09	
Dose (g/kg)	)	6-7 (2-0-10-6)	7-7 (3-7-14-6)	2-12 (-0-42 to 5-5	(8)	0.10	
Total Intrave	Feeding						
Total dextro	Breastfed babies		112	(95%)	113 (95%)		
Babies	Feeds per baby		13	(1-29)	11 (1-24)		
Dose (g/k Total dextro	Babies receiving expressed breastn	nilk	100	(85%)	97 (82%)		
Babies	Feeds per baby			(1-15)	6 (1-16)		
Dose (g/k						20	
Feeding	Volume (mL/kg)			4 (0-1-96-1)	4.7 (0.0-4	3.0)	
Breastfed ba	Babies receiving Infant formula		68	(58%)	72 (60%)		
Feeds per	Feeds per baby		7	(1-21)	10 (1-24)		
Babies receiv	Volume (mL/kg)		41	(1-162)	58 (2-208)		1
Feeds per	Admitted to NICU						
Volume (r	Babies (n)		45	(38%)	55 (46%)		
recei							
eeds per Volume (r	For hypoglycaemia (n)		16	(14%)	30 (25%)		
	Data are n (%) or median (range), unless	otherwise indicated	. NICU=neonatal	intensive-care uni	t. *40% dextro	se given a	


Admitted to N Data are n (%) or median (range), unless otherwise indicated. NICU=neonatal intensive-care unit. \*40% dextrose given according to usual clinical guidelines after the baby Babies (n) had failed treatment. †Includes open-label and intravenous dextrose.

Table 2: Primary and secondary outcomes

Data are n (%) or median (range), unless otherwise indicated. Nicul-neonatal intensive-care unit. 140% dextrose given according to usual clinical guidelines after the baby had failed treatment. Findudes open-label and intravenous dextrose.

Table 2: Primary and secondary outcomes

For hypogly -



Monday, August 28, 17

# ABM PROTOCOL Guidelines 2017

Monday, August 28, 17

# ABM PROTOCOL Guidelines 2017

"40% dextrose gel applied to the side of the infant's cheek is effective in increasing blood glucose levels in Asymptomatic hypoglycemia unresponsive to frequent breastfeeding, and improves the rate of exclusive breastfeeding after discharge with no evidence of adverse effects".

# ABM PROTOCOL Guidelines 2017

"40% dextrose gel applied to the side of the infant's cheek is effective in increasing blood glucose levels in Asymptomatic hypoglycemia unresponsive to frequent breastfeeding, and improves the rate of exclusive breastfeeding after discharge with no evidence of adverse effects".

Monday, August 28, 17

## WHAT ABOUT THE BRAIN?

# WHAT ABOUT THE BRAIN?

## 2015 and 2017 - McKinlay et al

- Children with Hypoglycemia and Later Development (CHYLD)

- Sugar Babies Study (n=514, >35 wks) & Babies and Blood Sugar's Influence on EEG study (n=102, >32 wks)

- Assess effects of transitional hypoglycemia

# WHAT ABOUT THE BRAIN?

## 2015 and 2017 - McKinlay et al

- Children with Hypoglycemia and Later Development (CHYLD)

- Sugar Babies Study (n=514, >35 wks) & Babies and Blood Sugar's Influence on EEG study (n=102, >32 wks)

- Assess effects of transitional hypoglycemia

## **2015**:

- 528 (86%) eligible for follow-up at 2 years (> 35 weeks)

- 76% of eligible infants assessed
- 53% had HG: 1 BG< 47; severe episode < 36; or recurrent (> 3 episodes)

## **Conclusion at age 2:**

No risk of neurosensory impairment or processing difficulty

## Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years

Christopher J. D. McKinlay, PhD; Jane M. Alsweiler, PhD; Nicola S. Anstice, PhD; Nataliia Burakevych, PhD; Arijit Chakraborty, PhD; J. Geoffrey Chase, PhD; Gregory D. Gamble, MSc; Deborah L. Harris, PhD; Robert J. Jacobs, PhD; Yannan Jiang, PhD; Nabin Paudel, PhD; Ryan J. San Diego, MSc; Benjamin Thompson, DPhil; Trecia A. Wouldes, PhD; Jane E. Harding, DPhil; for the Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

### JAMA Pediatrics, August 2017

## Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years

Christopher J. D. McKinlay, PhD; Jane M. Alsweiler, PhD; Nicola S. Anstice, PhD; Nataliia Burakevych, PhD; Arijit Chakraborty, PhD; J. Geoffrey Chase, PhD; Gregory D. Gamble, MSc; Deborah L. Harris, PhD; Robert J. Jacobs, PhD; Yannan Jiang, PhD; Nabin Paudel, PhD; Ryan J. San Diego, MSc; Benjamin Thompson, DPhil; Trecia A. Wouldes, PhD; Jane E. Harding, DPhil; for the Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

### JAMA Pediatrics, August 2017

## McKinlay et al.

Monday, August 28, 17

## Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years

Christopher J. D. McKinlay, PhD; Jane M. Alsweiler, PhD; Nicola S. Anstice, PhD; Nataliia Burakevych, PhD; Arijit Chakraborty, PhD; J. Geoffrey Chase, PhD; Gregory D. Gamble, MSc; Deborah L. Harris, PhD; Robert J. Jacobs, PhD; Yannan Jiang, PhD; Nabin Paudel, PhD; Ryan J. San Diego, MSc; Benjamin Thompson, DPhil; Trecia A. Wouldes, PhD; Jane E. Harding, DPhil; for the Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

### JAMA Pediatrics, August 2017

## McKinlay et al.

- Assessed 477/604 eligible children from CHYLD (sugar babies) + 102 BABIES

- 38 were 32 to 34 weeks; rest > 35 weeks

## Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years

Christopher J. D. McKinlay, PhD; Jane M. Alsweiler, PhD; Nicola S. Anstice, PhD; Nataliia Burakevych, PhD; Arijit Chakraborty, PhD; J. Geoffrey Chase, PhD; Gregory D. Gamble, MSc; Deborah L. Harris, PhD; Robert J. Jacobs, PhD; Yannan Jiang, PhD; Nabin Paudel, PhD; Ryan J. San Diego, MSc; Benjamin Thompson, DPhil; Trecia A. Wouldes, PhD; Jane E. Harding, DPhil; for the Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

### JAMA Pediatrics, August 2017

## McKinlay et al.

- Assessed 477/604 eligible children from CHYLD (sugar babies) + 102 BABIES
   38 were 32 to 34 weeks; rest > 35 weeks
- ICG + BG q3-4 hrs x 24 hrs, q 6-8hx24 up to 7 days

## Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years

Christopher J. D. McKinlay, PhD; Jane M. Alsweiler, PhD; Nicola S. Anstice, PhD; Nataliia Burakevych, PhD; Arijit Chakraborty, PhD; J. Geoffrey Chase, PhD; Gregory D. Gamble, MSc; Deborah L. Harris, PhD; Robert J. Jacobs, PhD; Yannan Jiang, PhD; Nabin Paudel, PhD; Ryan J. San Diego, MSc; Benjamin Thompson, DPhil; Trecia A. Wouldes, PhD; Jane E. Harding, DPhil; for the Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

### JAMA Pediatrics, August 2017

## McKinlay et al.

- Assessed 477/604 eligible children from CHYLD (sugar babies) + 102 BABIES
  38 were 32 to 34 weeks; rest > 35 weeks
- ICG + BG q3-4 hrs x 24 hrs, q 6-8hx24 up to 7 days

HG was NOT associated with major neurological deficits.

## Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years

Christopher J. D. McKinlay, PhD; Jane M. Alsweiler, PhD; Nicola S. Anstice, PhD; Nataliia Burakevych, PhD; Arijit Chakraborty, PhD; J. Geoffrey Chase, PhD; Gregory D. Gamble, MSc; Deborah L. Harris, PhD; Robert J. Jacobs, PhD; Yannan Jiang, PhD; Nabin Paudel, PhD; Ryan J. San Diego, MSc; Benjamin Thompson, DPhil; Trecia A. Wouldes, PhD; Jane E. Harding, DPhil; for the Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

### JAMA Pediatrics, August 2017

## McKinlay et al.

- Assessed 477/604 eligible children from CHYLD (sugar babies) + 102 BABIES
  38 were 32 to 34 weeks; rest > 35 weeks
- ICG + BG q3-4 hrs x 24 hrs, q 6-8hx24 up to 7 days

## HG was NOT associated with major neurological deficits. 2-3 fold increased risk of poor executive and visual motor development

## Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years

Christopher J. D. McKinlay, PhD; Jane M. Alsweiler, PhD; Nicola S. Anstice, PhD; Nataliia Burakevych, PhD; Arijit Chakraborty, PhD; J. Geoffrey Chase, PhD; Gregory D. Gamble, MSc; Deborah L. Harris, PhD; Robert J. Jacobs, PhD; Yannan Jiang, PhD; Nabin Paudel, PhD; Ryan J. San Diego, MSc; Benjamin Thompson, DPhil; Trecia A. Wouldes, PhD; Jane E. Harding, DPhil; for the Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

### JAMA Pediatrics, August 2017

## McKinlay et al.

- Assessed 477/604 eligible children from CHYLD (sugar babies) + 102 BABIES
  38 were 32 to 34 weeks; rest > 35 weeks
- ICG + BG q3-4 hrs x 24 hrs, q 6-8hx24 up to 7 days

## HG was NOT associated with major neurological deficits. 2-3 fold increased risk of poor executive and visual motor development

- <u>Conclusions</u>: Factors that increased risk of low EF/visual motor scores Severe hypoglycemia < 36 - >3 episodes

## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

JAMA Pediatrics, August 2015



## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

### JAMA Pediatrics, August 2015

# Can ONE single early transient low BG (<3 hrs) be associated with poor academic performance?



Monday, August 28, 17

## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

### JAMA Pediatrics, August 2015

# Can ONE single early transient low BG (<3 hrs) be associated with poor academic performance?

- Retrospective cohort study in 1998 at Arkansas



### Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

### JAMA Pediatrics, August 2015

- Retrospective cohort study in 1998 at Arkansas
- 1943 born at Arkansas center, min 1 recorded BG



## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

### JAMA Pediatrics, August 2015

# Can ONE single early transient low BG (<3 hrs) be associated with poor academic performance?

- Retrospective cohort study in 1998 at Arkansas
- 1943 born at Arkansas center, min 1 recorded BG
- Universal BG screen. Babies 23-42 wks



Monday, August 28, 17

## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

### JAMA Pediatrics, August 2015

- Retrospective cohort study in 1998 at Arkansas
- 1943 born at Arkansas center, min 1 recorded BG
- Universal BG screen. Babies 23-42 wks
- 1395 newborn-student pairs (72%)



## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

### JAMA Pediatrics, August 2015

- Retrospective cohort study in 1998 at Arkansas
- 1943 born at Arkansas center, min 1 recorded BG
- Universal BG screen. Babies 23-42 wks
- 1395 newborn-student pairs (72%)
- 440 (31.5%) preterm



## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

### JAMA Pediatrics, August 2015

- Retrospective cohort study in 1998 at Arkansas
- 1943 born at Arkansas center, min 1 recorded BG
- Universal BG screen. Babies 23-42 wks
- 1395 newborn-student pairs (72%)
- 440 (31.5%) preterm
- Eval infants with BG < 35 < 40 < 45



## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

### JAMA Pediatrics, August 2015

# Can ONE single early transient low BG (<3 hrs) be associated with poor academic performance?

- Retrospective cohort study in 1998 at Arkansas
- 1943 born at Arkansas center, min 1 recorded BG
- Universal BG screen. Babies 23-42 wks
- 1395 newborn-student pairs (72%)
- 440 (31.5%) preterm
- Eval infants with BG < 35 < 40 < 45

### Early transient HG was associated with



## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD

### JAMA Pediatrics, August 2015

# Can ONE single early transient low BG (<3 hrs) be associated with poor academic performance?

- Retrospective cohort study in 1998 at Arkansas
- 1943 born at Arkansas center, min 1 recorded BG
- Universal BG screen. Babies 23-42 wks
- 1395 newborn-student pairs (72%)
- 440 (31.5%) preterm
- Eval infants with BG < 35 < 40 < 45

# Early transient HG was associated with lower achievement test scores at 10 yo.



## Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency A Population-Based Study

Jeffrey R. Kaiser, MD, MA; Shasha Bai, PhD; Neal Gibson, PhD; Greg Holland, PhD; Tsai Mei Lin, MS; Christopher J. Swearingen, PhD; Jennifer K. Mehl, MD; Nahed O. ElHassan, MD


### JAMA Pediatrics, August 2015

# Can ONE single early transient low BG (<3 hrs) be associated with poor academic performance?

- Retrospective cohort study in 1998 at Arkansas
- 1943 born at Arkansas center, min 1 recorded BG
- Universal BG screen. Babies 23-42 wks
- 1395 newborn-student pairs (72%)
- 440 (31.5%) preterm
- Eval infants with BG < 35 < 40 < 45

Early transient HG was associated with lower achievement test scores at 10 yo. (proficiency on literacy and mathematics)





Monday, August 28, 17

### **Implemented a Protocol:**

Monday, August 28, 17

**Implemented a Protocol:** 

### "Using Glucose Gel to Treat Neonatal Hypoglycemia"

**Implemented a Protocol:** 

"Using Glucose Gel to Treat Neonatal Hypoglycemia"

Lack of clinical evidence defining pathologic glucose levels.

Monday, August 28, 17

**Implemented a Protocol:** 

"Using Glucose Gel to Treat Neonatal Hypoglycemia"
Lack of clinical evidence defining pathologic glucose levels.
AAP guidelines 2011--> BG 25 mg/dl

**Implemented a Protocol:** 

**"Using Glucose Gel to Treat Neonatal Hypoglycemia"**Lack of clinical evidence defining pathologic glucose levels.
AAP guidelines 2011--> BG 25 mg/dl
Hypoglycemia = NICU, Separation, delay BF and bonding

**Implemented a Protocol:** 

\*Using Glucose Gel to Treat Neonatal Hypoglycemia
Lack of clinical evidence defining pathologic glucose levels.
AAP guidelines 2011--> BG 25 mg/dl
Hypoglycemia = NICU, Separation, delay BF and bonding
Formula=N egatively affects gut, changes gut flora for up to 4 weeks

**Implemented a Protocol:** 

\*Using Glucose Gel to Treat Neonatal Hypoglycemia
Lack of clinical evidence defining pathologic glucose levels.
AAP guidelines 2011--> BG 25 mg/dl
Hypoglycemia = NICU, Separation, delay BF and bonding
Formula=N egatively affects gut, changes gut flora for up to 4 weeks

**Implemented a Protocol:** 

\*Using Glucose Gel to Treat Neonatal Hypoglycemia
Lack of clinical evidence defining pathologic glucose levels.
AAP guidelines 2011--> BG 25 mg/dl
Hypoglycemia = NICU, Separation, delay BF and bonding
Formula=N egatively affects gut, changes gut flora for up to 4 weeks

- Retrospective chart review:

Retrospective chart review:
 870 newborns at risk (March 2013 - May 2014)

Retrospective chart review:
 870 newborns at risk (March 2013 - May 2014)
 1089 charts after implementation (May 14- July 15)


Retrospective chart review:
 870 newborns at risk (March 2013 - May 2014)
 1089 charts after implementation (May 14- July 15)


- Used Commercial gel available in the hospital pharmacy

Retrospective chart review:
 870 newborns at risk (March 2013 - May 2014)
 1089 charts after implementation (May 14- July 15)

- Used Commercial gel available in the hospital pharmacy

- First-line treatment if BG < 35 mg/dl at 30 minutes after first feeding.






#### BOX 3 Basic Steps in Our Glucose Gel Algorithm


- Neonates are placed skin to skin and breastfed within the first hour of life.
- A BG level is obtained 30 minutes after this feeding is completed.
- If the BG level is <35 mg/dl, the nurse administers a weight-based dose of 40% glucose gel by syringe to the neonate's buccal cavity and then places the neonate with the mother to feed.
- A BG level is then repeated 1 hour after gel administration.
- If this BG level is >35 mg/dl, the neonate's BG levels are assessed before feedings until two consecutive readings are >45 mg/dl.
- If the neonate's BG level is <35 mg/dl, a second dose of the gel is administered, and the neonate is again placed with the mother to feed.
- In the event that a second dose is needed, a BG level is obtained 1 hour after gel administration.
- If hypoglycemia is not reversed after the second dose of 40% glucose, the physician is contacted for further orders.

Note. BG = bedside glucose.

#### FIGURE 1 Percentage of Infants Admitted to NICU for Neonatal Hypoglycemia



"This safe and effective intervention resulted in a 73% decrease in NICU admissions for the diagnosis of neonatal hypoglycemia over a 14-month period"



Monday, August 28, 17

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

### • RDBPC Dose finding trial of buccal DG to prevent HG

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

RDBPC Dose finding trial of buccal DG to prevent HG
2 Hospitals in New Zealand. 2013-2014, 416 babies

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

RDBPC Dose finding trial of buccal DG to prevent HG
2 Hospitals in New Zealand. 2013-2014, 416 babies
Babies at risk: IDM, LGA, SGA, LPI

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

RDBPC Dose finding trial of buccal DG to prevent HG
2 Hospitals in New Zealand. 2013-2014, 416 babies
Babies at risk: IDM, LGA, SGA, LPI

• 4 treatment Groups or 4 Placebo groups:

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

RDBPC Dose finding trial of buccal DG to prevent HG
2 Hospitals in New Zealand. 2013-2014, 416 babies
Babies at risk: IDM, LGA, SGA, LPI

 4 treatment Groups or 4 Placebo groups: 40% DG 0.5 ml/kg = 200 mg/kg x 1 at 1 hr old

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

RDBPC Dose finding trial of buccal DG to prevent HG
2 Hospitals in New Zealand. 2013-2014, 416 babies
Babies at risk: IDM, LGA, SGA, LPI

 4 treatment Groups or 4 Placebo groups: 40% DG 0.5 ml/kg = 200 mg/kg x 1 at 1 hr old 40% DG 0.5 ml/kg = 200 mg/kg x 1+ 3 doses

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*


RDBPC Dose finding trial of buccal DG to prevent HG
2 Hospitals in New Zealand. 2013-2014, 416 babies
Babies at risk: IDM, LGA, SGA, LPI
4 treatment Groups or 4 Placebo groups: 40% DG 0.5 ml/kg = 200 mg/kg x 1 at 1 hr old 40% DG 0.5 ml/kg = 200 mg/kg x 1+ 3 doses 40% DG 1 ml/kg = 400 mg/kg x 1

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

RDBPC Dose finding trial of buccal DG to prevent HG
2 Hospitals in New Zealand. 2013-2014, 416 babies
Babies at risk: IDM, LGA, SGA, LPI
4 treatment Groups or 4 Placebo groups: 40% DG 0.5 ml/kg = 200 mg/kg x 1 at 1 hr old 40% DG 0.5 ml/kg = 200 mg/kg x 1+ 3 doses 40% DG 1 ml/kg = 400 mg/kg x 1

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

RDBPC Dose finding trial of buccal DG to prevent HG
2 Hospitals in New Zealand. 2013-2014, 416 babies
Babies at risk: IDM, LGA, SGA, LPI
4 treatment Groups or 4 Placebo groups: 40% DG 0.5 ml/kg = 200 mg/kg x 1 at 1 hr old 40% DG 0.5 ml/kg = 200 mg/kg x 1+ 3 doses
40% DG 1 ml/kg = 400 mg/kg x 1 40% DG 1 ml/kg = 400 mg/kg + 3 doses
Primary outcome: HG(<47mg/dl) in the first 48 h</li>



Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

Risk of HG was lowest in babies randomized to a **single dose of 200 mg/kg DG** (relative risk [RR] 0.68; 95% [CI] 0.47–0.99, p = 0.04) than placebo, but was NOT significantly different between dose groups (p = 0.21).

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

Risk of HG was lowest in babies randomized to a **single dose of 200 mg/kg DG** (relative risk [RR] 0.68; 95% [CI] 0.47–0.99, p = 0.04) than placebo, but was NOT significantly different between dose groups (p = 0.21).

Rates of NICU admission were similar

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

Risk of HG was lowest in babies randomized to a **single dose of 200 mg/kg DG** (relative risk [RR] 0.68; 95% [CI] 0.47–0.99, p = 0.04) than placebo, but was NOT significantly different between dose groups (p = 0.21).

- Rates of NICU admission were similar
- Admission for HG was less common

Joanne Elizabeth Hegarty<sup>1,2</sup>, Jane Elizabeth Harding<sup>1</sup>, Gregory David Gamble<sup>1</sup>, Caroline Anne Crowther<sup>1</sup>, Richard Edlin<sup>3</sup>, Jane Marie Alsweiler<sup>1,2,4</sup>\*

Risk of HG was lowest in babies randomized to a **single dose of 200 mg/kg DG** (relative risk [RR] 0.68; 95% [CI] 0.47–0.99, p = 0.04) than placebo, but was NOT significantly different between dose groups (p = 0.21).

- Rates of NICU admission were similar
- Admission for HG was less common

## Kaiser WCR & SSC

## **Dextrose Gel PILOT (July 2017-)**



Monday, August 28, 17

# Kaiser WCR & SSC

## **Dextrose Gel PILOT (July 2017-)**

### ★ "high risk": LGA, SGA, IDM, LPI



### **Dextrose Gel PILOT (July 2017-)**

#### ★ "high risk": LGA, SGA, IDM, LPI

**★**Neonates are placed skin to skin



- ★ "high risk": LGA, SGA, IDM, LPI
- **★**Neonates are placed skin to skin
- **★**Breastfed for first hour of life



- ★ "high risk": LGA, SGA, IDM, LPI
- **★**Neonates are placed skin to skin
- **★**Breastfed for first hour of life
- **★**BG at 30 min after feed



- ★ "high risk": LGA, SGA, IDM, LPI
- **★**Neonates are placed skin to skin
- **★**Breastfed for first hour of life
- **★**BG at 30 min after feed
- ★IF BG <35 mg/dl --> 40% Dextrose gel, then baby back with mother to feed



- ★ "high risk": LGA, SGA, IDM, LPI
- **★**Neonates are placed skin to skin
- **★**Breastfed for first hour of life
- **★**BG at 30 min after feed
- ★IF BG <35 mg/dl --> 40% Dextrose gel, then baby back with mother to feed
- **★**Repeat BG 1 hour after gel



### Kaiser WCR & SSC Dextrose Gel PILOT (July 2017-)

#### POCT HYPOGLYCEMIA SCREENING PILOT PROTOCOL WITH USE OF DEXTROSE GEL

=== Protocol is only for asymptomatic infants at risk of hypoglycemia===

Infants at risk of hypoglycemia s are: 1) Infants of diabetic mothers 2) Late preterm infants (GA less than 37weeks) 3) Infants with birth weights less than 10th percentile OR greater than 90th percentile per Fenton growth curves.

#### Screening 0 until 4 Hrs of Life:

If initial AC/PC glucose >/= to 40 continue AC checks next feeding. If initial AC/PC glucose less than 25-394, feed1 baby and re-check glucose in 1 hr2. If initial AC/PC glucose less than 254, give **dextrose gel3 (0.5mL/kg)** then feed1 and re-check glucose in 1hr2.

If repeat glucose in 1 hr >/= to 40, continue AC checks at next feed. If repeat glucose 25-39, give dextrose gel3 (0.5mL/kg) then feed and recheck glucose in 1 hr

If repeat glucose <25, notify MD.


#### Screening 4-24 Hrs of Life:


If AC glucose >/= to 45, continue AC checks with next feeding. If AC glucose <454, give dextrose gel (0.5mL/kg) then feed1, re-check glucose in 1 hr2.

If repeat glucose in 1 hr >/= to 45, continue AC checks at next feed.

If repeat glucose 35-44, give dextrose gel (0.5mL/kg) then feed1 and recheck glucose in 1 hr

If repeat glucose less than 35, notify MD.







- 5 Weeks of Implementation



- 5 Weeks of Implementation
- Gel given 36 times to 25 babies



- 5 Weeks of Implementation
- Gel given 36 times to 25 babies
- 2 babies to NICU after "failed" gel



- 5 Weeks of Implementation
- Gel given 36 times to 25 babies
- 2 babies to NICU after "failed" gel

### - 92% Success rate



- 5 Weeks of Implementation
- Gel given 36 times to 25 babies
- 2 babies to NICU after "failed" gel

### - 92% Success rate

- ~ 60% responded to 1 dose



- 5 Weeks of Implementation
- Gel given 36 times to 25 babies
- 2 babies to NICU after "failed" gel

### - 92% Success rate

- ~ 60% responded to 1 dose
- Most babies: LPIs & IDM



- 5 Weeks of Implementation
- Gel given 36 times to 25 babies
- 2 babies to NICU after "failed" gel

### - 92% Success rate

- ~ 60% responded to 1 dose
- Most babies: LPIs & IDM
- NO adverse events



#### KAISER PERMANENTE HEALTH**CONNECT**...

#### Hypoglycemia screening Guidelines for Asymptomatic At Risk Newborns

Check Glucose on any infant who has symptoms of hypoglycemia (irritability, tremors, jitteriness, exaggerated Moro reflex, high pitched cry, lethargy, floppiness, cyanosis, seizures, apnea or poor feeding)

NOTIFY MD ABOUT SYMPTOMATIC INFANTS AFTER CHECKING SUGARS, REGARDLESS OF THE RESULT.

#### Patients Requiring 12 hour Screening

- All Infants of diabetic mothers
  Infants > 4 Kg
- Screen every 3 hours AC for 12 hours (4 screens)

#### Patients requiring 24 hour screening

Late preterm infants (GA less than 37weeks)
 Infants < 2.5 Kg</li>

Screen every 3 hours AC for 12 hours and also at 15-18 hrs and at 21-24 hrs old (6 screens)

#### SCREENING 0-4 HOURS OF LIFE

Feed within 1 hour of life. First screen 30 min after feeding. If unable to feed check at 1 hour.

Feeds are either ad lib breastfeedings OR syringe feeding of EBM if available OR a combination of both. Only a baby who is exclusively formula feeding due to medical reasons or due to maternal choice or per physician orders, will get formula feeding.

#### Re-checks for glucose are to be done 1 hour after the end of the feeding.

If initial AC/PC glucose greater than or equal to 40 continue AC checks next feeding. If initial AC/PC glucose between 25-39, feed baby and re-check glucose in 1 hr. If initial AC/PC glucose less than 25, give **Dextrose gel 2 ml** then feed and re-check glucose in 1hr.

If repeat glucose in 1 hr >/= to 40, continue AC checks at next feed. If repeat glucose 25-39, give **Dextrose gel 2ml** then feed and re-check glucose in 1 hr. If repeat glucose <25, notify MD: Consider 3<sup>rd</sup> dose of gel, if formula feeding increase volume. Consider introduction of formula feeding. If these actions ineffective, IV therapy.

#### SCREENING 4-24 HOURS OF LIFE

Continue screening before feeding every 3 hours for 12 or 24 hours

Feeds are either ad lib breastfeedings OR syringe feeding of EBM if available OR a combination of both. Only a baby who is exclusively formula feeding due to medical reasons or due to maternal choice or per physician orders, will get formula feeding.

If AC glucose >/= to 45, continue AC checks with next feeding.

If AC glucose <45, give **Dextrose gel 2ml** then feed, re-check glucose in 1 hr.

If repeat glucose in 1 hr >/= to 45, continue AC checks at next feed.

If repeat glucose 35-44, give **Dextrose gel 2ml** then feed and re-check glucose in 1 hr If repeat glucose less than 35, notify MD for consideration of IV therapy.

If discharged at </= 24 hours, the last 2 consecutive blood sugars must be >45 mg/dl. If discharged at >24 hours patient must have one documented blood sugar > 55 mg/dl.



## FUTURE DIRECTIONS



# ★ Revise current cut-offs for treatment based on hours of age - Higher thresholds?

## FUTURE DIRECTIONS



 ★ Revise current cut-offs for treatment based on hours of age - Higher thresholds?
 ★ Simplify current screening protocols: Same frequency and duration for all at-risk groups?

## FUTURE DIRECTIONS



 ★ Revise current cut-offs for treatment based on hours of age - Higher thresholds?
 ★ Simplify current screening protocols: Same frequency and duration for all at-risk groups?
 ★ Use of Dextrose Gel Prophylasix in High risk?

## FUTURE DIRECTIONS



 ★ Revise current cut-offs for treatment based on hours of age - Higher thresholds?
 ★ Simplify current screening protocols: Same frequency and duration for all at-risk groups?
 ★ Use of Dextrose Gel Prophylasix in HIgh risk?
 ★ Follow closely emerging OUTCOME DATA

## FUTURE DIRECTIONS





ah freeze" is trig

martice cream touch

your mouth, Car

vessels in the he

## **KEEP YOUR** BABIES SWEET!